-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]acetamide (MRS1706) completely abrogated the A 2A receptor agonistmediated effect on TSP1. Vascular tube formation by HMVEC was increased by adenosine A 2A receptor agonists in a dosedependent fashion (EC 50 ϭ 0.1 M for both), and this effect was reversed by the A 2A antagonist. Moreover, in the presence of antibodies to TSP1 and CD36, the receptor for TSP1, the adenosine A 2A receptor agonists stimulated no increase in vascular tube formation. These results indicate that the angiogenic effects of adenosine A 2A receptor activation are, at least in part, caused by the suppression of TSP1 secretion.
antagonist 4-{2-[7-amino-2-(2-furyl) [1, 2, 4] triazolo- [2,3-a] [1, 3, 5] triazin-5-ylamino]ethyl}phenol (ZM241385) but not the A1 and A 2B receptor antagonists diphenylcyclopentylxanthine, enprofylline, and N-(4-acetylphenyl)-2-[4-(2,3,6,7-tetrahydro-2,6 -dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]acetamide (MRS1706) completely abrogated the A 2A receptor agonistmediated effect on TSP1. Vascular tube formation by HMVEC was increased by adenosine A 2A receptor agonists in a dosedependent fashion (EC 50 ϭ 0.1 M for both), and this effect was reversed by the A 2A antagonist. Moreover, in the presence of antibodies to TSP1 and CD36, the receptor for TSP1, the adenosine A 2A receptor agonists stimulated no increase in vascular tube formation. These results indicate that the angiogenic effects of adenosine A 2A receptor activation are, at least in part, caused by the suppression of TSP1 secretion.
Angiogenesis, the formation of new blood vessels from a pre-existing vasculature, is tightly regulated in normal adults. Growth of new capillaries is controlled by the interplay of growth regulatory factors, which either stimulate or inhibit blood vessel growth (Westphal et al., 2000; Medina et al., 2004; Nicholson and Theodorescu, 2004) . Many angiogenic factors have been described, including vascular endothelial growth factor, basic fibroblast growth factor, and thymidine phosphorylase. More recently, a number of naturally occurring inhibitors of angiogenesis, including thrombospondin and angiostatin, have also been identified (Liu et al., 1999; Westphal et al., 2000) .
Adenosine, a potent endogenous physiological mediator, regulates a wide variety of physiological processes. Adenosine mediates its physiological effects via interaction with one or more of four G protein-coupled receptors (A 1 , A 2A , A 2B , and A 3 ), expressed on many cell types, including neutrophils, macrophages, fibroblasts, and endothelial cells (Montesinos et al., 1997 (Montesinos et al., , 2000 Victor-Vega et al., 2002) . Recent studies in wild-type and adenosine A 2A receptor knockout mice demonstrate that adenosine A 2A receptor oc-cupancy stimulates angiogenesis and increases the rate at which wounds close (Montesinos et al., 1997 . Adenosine A 2A receptor-mediated regulation of angiogenic factors, such as VEGF (Feoktistov et al., 2002; Leibovich et al., 2002; Montesinos et al., 2002; Nguyen et al., 2003; Olah and Caldwell, 2003) , plays an important role in adenosine A 2A receptor-stimulated angiogenesis in healing wounds, but adenosine A 2A receptors may modulate other functions as well.
We report here that representational display analysis of medium-or CGS-21680 (an A 2A receptor agonist)-stimulated human umbilical vein endothelial cells identified adenosine A 2A receptor-mediated modulation of the antiangiogenic factor thrombospondin 1 (TSP1) as another potential contributor to A 2A receptor-stimulated angiogenesis. In support of this hypothesis, we found that adenosine A 2A receptor agonists suppressed TSP1 mRNA and protein expression. Studies of vascular tube formation on Matrigel further demonstrate that adenosine A 2A receptor-mediated suppression of TSP1 expression plays an important role in adenosine A 2A receptor-mediated enhancement of angiogenesis.
Reverse Transcription. All reverse-transcription reactions and PCRs were carried out in a GeneAmp PCR System 2400 thermal cycler (PerkinElmer Life and Analytical Sciences, Boston, MA). For each assay, 1 g of mRNA was reverse-transcribed using 50 U of murine leukemia virus reverse transcriptase (Applied Biosystems, Foster City, CA) in a final volume of 50 l. The reaction mixtures were incubated at 42°C for 45 min followed by inactivation at 95°C for 5 min and finally cooled to 5°C for 5 min.
Polymerase Chain Reaction. cDNA (5 l) was used for both TSP1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RT-PCR amplification. The upstream and downstream primers for TSP1 and GAPDH were the following: 5Ј-CCTGATGGAGAATGCTGTCC-3Ј and 5Ј-CACATCGGTTGTTGAGGCTA-3Ј(NYU CORE facility), and 5Ј-TGAAGGTCGGAGTCAACGGATTTGGT-3Ј and 5Ј-CATGTGGGCCA-TGAGGTCCACCAC-3Ј, respectively (Sigma-Aldrich). The PCR reaction was carried out using PCR kit (Applied Biosystems) and 0.15 M concentration of each upstream and downstream primer per reaction. The PCR protocol included 40 cycles at 95°C for 1 min, 55°C for 1 min, and 72°C for 1 min for TSP1 and 94°C for 45 s, 58°C for 1 min, and 72°C for 1 min for GAPDH.
PCR Product Confirmation. The PCR products (10 l/lane) were mixed with 1 l of 6ϫ DNA loading buffer (Invitrogen) and loaded directly onto a 1% agarose gel. The GAPDH controls (10 l/lane) were loaded at two concentrations, 1 and 0.20 g/l RNA. The PCR products were visualized and photographed under ultraviolet light (320 nm) using a Kodak transilluminator (Eastman Kodak, Rochester, NY). The band intensities were measured with Kodak Digital Science 1D, version 2.0.3, after imaging with Kodak Digital Science Electrophoresis Documentation and Analysis System 120 (Eastman Kodak). All experimental results were normalized to the intensity of GAPDH.
Generation of a Subtraction Library. HUVECs were grown to 70% confluence in T75 flasks. The night before the experiment, cells were refed with fresh media. After 4-h incubation of HUVEC with fully supplemented Dulbecco's modified Eagle's medium (10% fetal bovine serum, L-glutamine, and penicillin/streptomycin) in the presence or absence of 1 M selective adenosine A 2A receptor agonist, poly(A) ϩ mRNA was isolated using a microFastTrack mRNA Isolation Kit (Invitrogen) according to manufacturer's instructions. Then, cDNA was prepared using a RiboClone cDNA Synthesis System according to the manufacturer's instructions (Promega, Madison, WI). The subtraction library was generated using the cDNA representational difference analysis (RDA) developed by Chu and Paul (1998) . In brief, cDNA was digested by Sau3AI (New England Biolabs, Beverly, MA) at 37°C under conditions suggested by the manufacturer, followed by incubation at 65°C for 20 min to stop the reaction. Driver amplicon (from untreated cells) and tester amplicon (from CGS-21680-treated cells) were generated by annealing specific sets of adaptors to the digested cDNA and subsequent PCR amplification as described previously. Driver amplicon was then modified by reamplification with 5Ј-biotinylated adaptor primer. We performed four rounds of subtractions in hybridization buffer (0.5 M phosphate buffer, 0.1% SDS, and 5 mM EDTA) at 65°C after denaturation at 100°C for 5 min. Driver-tester and driver-driver hybrids were removed by magnetic-bead depletion (Dynabeads M-280 Streptavidin; 
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Dynal Biotech, Lake Success, NY). Tester-tester hybrids were then amplified using a primer specific for the adaptor sequence ligated on the tester strand. Amplified material was digested with Sau3AI, purified with Chromaspin-100 columns, ligated into BamHI (NEB) site of pBluescriptSK ϩ (Stratagene, La Jolla, CA), and transformed into DH5␣ bacteria (Invitrogen) on selective plates (Luria-Bertani medium with agar and 100 g/ml ampicillin supplemented with Xgal IPTG; MP Biomedicals, Irvine, CA). Individual transformants were analyzed for DNA insert by PCR. Products larger than 164 base pairs indicated that an insert had been cloned. These subtraction clone inserts were sequenced from purified plasmid DNA in the core sequencing facility at New York University School of Medicine (New York, NY). Sequences were analyzed using Sequencher and compared with public databases by using BLAST service provided by the National Center for Biotechnology Information (Bethesda, MD) ( Table 2) . Southern Blot Analysis. For analysis of RDA amplicons, driver, tester, and amplicon samples (ϳ0.25 g) were separated on a 2% agarose gel and Southern blotted to nylon membrane (Optitran; Schleicher & Schuell, Keene, NH) by upward capillary in 10ϫ SSC buffer (1.5 M NaCl and 0.15 M sodium citrate, pH 7.0). After UV cross-linking with a UV cross-linker (Fisher Scientific Co., Pittsburgh, PA), membranes were prehybridized for 3 h at 65°C in prehybridization solution (Amersham Biosciences Inc., Piscataway, NJ) and then hybridized overnight at 65°C to radioactive-labeled probe in hybridization solution (Amersham Biosciences). GAPDH and VEGF probes were generated by PCR from HUVEC cDNA using 5Ј-gaccccttcattgacctcaac-3Ј forward and 5Ј-gaggggccatccacagtcttc-3Ј reverse primers for GAPDH and from 5Ј-cgccatcctgtgtgccc-3Ј forward and 5Ј-ctcaccgcctcggcttgtc-3Ј reverse primers for VEGF. Probes were labeled with [␣- 32 P]dCTP (3000 Ci/mmol; Amersham Biosciences) using an Oligo Labeling Kit (Pfizer, Inc., New York, NY). After hybridization, the membranes were washed twice in 1ϫ SSC and 0.1% SDS at room temperature, twice in 1ϫ SSC and 0.1% SDS at 65°C, and twice in 0.1ϫ SSC and 0.1% SDS at 65°C and air-dried. Radioactivity was analyzed and quantified by PhosphorImager (Amersham Biosciences). For differential screening, PCR products of inserts from individual subtraction clones (ϳ0.25 g) were electrophoresed in 2% agarose gels and then treated as described above. Membranes were probed as above with [␣- 32 P]dCTP-labeled driver or tester amplicon. Intensity of hybridization signal between tester and driver amplicon probes on each individual PCR product was compared by densitometric measurements of bands using Kodak Digital Science software (Eastman Kodak).
Northern Blot Analysis. HMVEC were incubated with adenosine receptor agonists as described above. As described previously, denatured RNA samples (10 g) were electrophoresed in 1% agarose/ formaldehyde gels and Northern-blotted to supported nitrocellulose membrane (Optitran; Schleicher & Schuell) by downward capillary method in 20ϫ SSC (0.15 M NaCl plus 0.015 M sodium citrate). HUVEC were incubated for 4 h in the presence or absence of 1 M selective adenosine A 2A receptor agonist, CGS-21680. The subtraction library was generated using the cDNA representational difference analysis as described under Materials and Methods. Products larger than 164 base pairs indicate that an insert had been cloned. PCR products of inserts from individual clones were identified, analyzed using Sequencher, and compared with public databases by using BLAST. Column 1 indicates the number of hits for the protein mentioned in column 2. Thereafter, the membrane was rinsed in 2ϫ SSC, air-dried, and UV-cross-linked with UV cross-linker (Fisher Scientific), prehybridized for 3 h at 65°C in prehybridization solution (Amersham Biosciences), and then probed with [␣-32 P]dCTP (3000 Ci/mmol; Amersham Biosciences)-labeled PCR products of individual subtraction clones overnight at 65°C in a hybridization oven (Fisher Scientific). After multiple washes in 1ϫ, 0.5ϫ, and 0.2ϫ SSC, membranes were air-dried, and radioactivity was analyzed and quantified as described above.
Number of
Western Blot Analysis. TSP1 concentration was determined semiquantitatively by Western Blot. HMVECs were treated with CGS-21680 or MRE0094. After 24-h treatment, supernates were collected. A 20-l sample of protein supernates was fractionated onto a 7.5% SDS-PAGE and transferred onto a nitrocellulose membrane (Bio-Rad, Hercules, CA). After transfer, the nitrocellulose membrane was stained with 0.1% Ponceau (Sigma-Aldrich) and scanned with a Microtek scanner. The net intensities were measured with Kodak Digital Science 1D, version 2.0.3. After removing the stain with distilled water, the nitrocellulose membrane was blocked for 4 h at 4°C in blocking solution (3% nonfat dry milk in 1ϫ Tris-buffered saline/Tween 20). The membrane was incubated at 4°C overnight on a rocker with blocking solution containing a 1:200 dilution of primary antibody (200 g/ml) for anti-angiogenic factor TSP1 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and thereafter incubated with alkaline phosphatase-labeled anti-goat secondary antibody (Santa Cruz Biotechnology). The protein bands were visualized using the ECF kit (Amersham Biosciences) and were quantified with ImageQuant intensity software program (Amersham Biosciences). Ponceau staining was used as a normalization control.
Angiogenesis In Vitro Assay. HMVECs were cultured with EBM-2MV media up to 80 to 90% confluence in a T75. HMVEC suspension was prepared by digesting the cell monolayers with trypsin and resuspending in culture medium. Matrigel (50 l) (Chemicon International, Temecula, CA) was loaded into each well. A 200-l sample of cell suspension (5 ϫ 10 4 cells/ml) along with A 2A agonist CGS-21680 or MRE0094 ranging from 10 Ϫ5 M to 10 Ϫ9 M was added to each well. Appropriate antagonist (ZM241385, enprofylline, or DPCPX, each at 10 M) or the antibodies (anti-TSP1, anti-collagen 1 or anti-CD36, each at 1:50 dilution; Santa Cruz Biotechnology) or exogenous TSP1 protein at 10 g/ml was added. The angiogenesis assay plate was incubated for 16 to 18 h (37°C and 5% CO 2 ). Fluorophore/calcein AM (Molecular Probes, Eugene, OR) was used to stain the tubes. Image acquisition of endothelial cell tube formation was achieved by MetaMorph software coupled with an automated imager (Molecular Devices Corporation, Downingtown, PA). Sigma Scan Pro software was used to measured tube length and tube surface area, which are two parameters to quantify the overall tube formation. Statistical Analysis. Differences between groups were analyzed by means of one-and two-way analyses of variance using SigmaStat (SPSS Inc., Chicago, IL). Data are presented as means Ϯ S.E.M. Differences with a p value of Ͻ0.05 were considered significant.
Results
Adenosine A 2A Receptor Agonist Modulates Gene Expression in Endothelial Cells. To characterize adenosine A 2A receptor activation effects on endothelial cells, we used a sensitive PCR-based subtraction approach to isolate genes expressed after 4-h treatment with the selective A 2A agonist CGS-21680. Our approach, combined an adaptation of the genomic RDA method to cDNA analysis with a physical separation method (magnetic bead depletion). We isolated a total of 175 clones; six did not contain an insert, 34 did not match any known gene, three contained inserts that match ␤-actin but by Southern blot they were not modulated, and the rest are summarized in Table 2 .
Adenosine A 2A Receptor Occupancy Suppresses HMVEC Expression of TSP1 mRNA. Representational display analysis of mRNA from CGS-21680-treated and medium-treated human umbilical vein endothelial cells indicated that TSP1 message was modulated in the CGS-21680-treated cells. To confirm that TSP1 message was, in fact, down-regulated by A 2A receptor ligation we determined TSP1 mRNA levels in medium and 1 M CGS-21680-treated human microvascular endothelial cells (HMVEC). Northern blot analysis and semiquantitative RT-PCR demonstrated that CGS-21680 suppressed TSP1 message expression (Fig.  1) corroborating the results of the representational display analysis. Representational display analysis further indicated that expression of a number of other genes might also be regulated by adenosine A 2A receptor occupancy (Table 2) although the effects of adenosine A 2A receptor occupancy on expression of these gene products has not been confirmed.
Adenosine A 2A Receptor Occupancy Suppresses HMVEC Secretion of TSP1 Protein. We next examined the effects of adenosine A 2A receptor ligation on the expression of TSP1 protein by semiquantitative Western blot analysis. The selective adenosine A 2A receptor agonist CGS-21680 suppressed TSP1 secretion by HMVEC in a dosedependent fashion (EC 50 ϭ 6.65 nM) (Fig. 2) . To confirm the identity of the adenosine receptor involved in the suppression of TSP1, we determined the effect of selective adenosine receptor antagonists on the capacity of CGS-21680 to suppress TSP1 secretion by HMVECs. HMVECs express mes- (Nguyen et al., 2003) . The selective adenosine A 2A receptor antagonist ZM241385 (at both 10 M and 10 nM concentrations) but not the A 2B or A 1 receptor antagonists enprofylline, MRS1706, or DPCPX, respectively, completely reversed the effect of CGS-21680 on TSP1 secretion (Fig. 2) . Studies of the effect of another A 2A receptor agonist, MRE0094, on TSP1 secretion were nearly identical with those obtained with CGS-21680; MRE0094 inhibited TSP1 secretion in a dose-dependent fashion (EC 50 ϭ 0.23 M) (Fig.  3) . As with CGS-21680, ZM241385 but not enprofylline, MRS1706, or DPCPX reversed the effects of MRE0094 on TSP1 secretion (Fig. 3) . Thus, pharmacological studies indicate that occupancy of adenosine A 2A receptors suppresses secretion of the anti-angiogenic protein TSP1. (Figs. 4 and 5) . It is interesting that at a concentration at which CGS-21680 loses its selectivity for the A 2A receptor and stimulates the A 2B receptor, the effect on vascular tube formation is less marked (Fig. 5A ). MRE0094 stimulates vascular tube formation at all concentrations tested (Fig. 5B) . As with the effect of both CGS-21680 and MRE0094 on TSP1 secretion, ZM241385, but not enprofylline or DPCPX, completely abrogated the effect of both MRE0094 and CGS-21680 on vascular tube formation (Figs. 4 and 5) .
Antibody-Mediated Blockade of TSP1 and CD36, the Cell-Surface Receptor for TSP1, Abrogate the Effect of Adenosine A 2A Receptor Occupancy on Vascular Tube Formation. The effects of adenosine A 2A receptor occupancy on TSP1 mRNA expression and protein secretion parallel those of A 2A receptor occupancy on vascular tube formation. To determine whether these two phenomena are related, we determined the effect of anti-TSP1 antibody on the capacity of adenosine A 2A receptor occupancy to stimulate vascular tube formation. Anti-TSP1, but not anti-collagen 1, antibodies increased vascular tube formation. As expected, in the presence of anti-TSP1 antibodies, the effects of CGS-21680 and MRE0094 on vascular tube formation were completely abrogated. As expected, exogenous TSP1 inhibits vascular tube formation, and neither CGS21680 nor MRE0094 increases tube formation in the presence of exogenous TSP1 (Fig. 6) . TSP1 promotes its antiangiogenic activity by binding to CD36 on the surface of HMVEC. Like antibodies to TSP1, antibodies to CD36 increased vascular tube formation and completely blocked the adenosine A 2A receptor-mediated promotion of vascular tube formation (Table 3) . These results are consistent with the hypothesis that adenosine A 2A receptor ligation promotes vascular tube formation (a measure of new vessel formation) by suppressing endogenous production of the antiangiogenic matrix protein TSP1.
Discussion
The results reported here demonstrate that adenosine A 2A receptor occupancy promotes angiogenesis, at least in part, by down-regulating the expression of TSP1, an antiangiogenic matrix protein. Two different adenosine A 2A receptor Data are expressed as the mean percentage control (S.E.M.) as described. The effect of CGS-21680 on tube formation was statistically significant (p ϭ 0.005, n ϭ 3, ANOVA). Anti-TSP1 IgG alone significantly increased vascular tube formation to 184 Ϯ 33% of control (p ϭ 0.005, n ϭ 7, two-way ANOVA), and there was no further effect of CGS-21680 in the presence of anti-TSP1. In the presence of anti-collagen 1, CGS21680 significantly increased tube formation (p Ͻ 0.001, n ϭ 3, two-way ANOVA). Exogenous TSP1 significantly decreased tube formation, and CGS-21680 did not increase tube formation in the presence of TSP1 (p Ͻ 0.001, n ϭ 3, two-way ANOVA). B, HMVECs were incubated on Matrigel overnight in the presence of MRE0094 alone, goat anti-TSP1 IgG, goat anti-collagen I IgG, or exogenous TSP1. The effect of MRE0094 on tube formation was statistically significant (p Ͻ 0.001, n ϭ 4, ANOVA). Anti-TSP1 IgG alone significantly increased vascular tube formation to 162.9 Ϯ 12.2% of control (p ϭ not significant, n ϭ 3, two-way ANOVA), and there was no further effect of MRE0094 in the presence of anti-TSP1. In the presence of anti-collagen 1, MRE0094 significantly increased tube formation (p ϭ 0.018, n ϭ 3, two-way ANOVA). Exogenous TSP1 significantly decreased tube formation, and MRE0094 did not increase tube formation in the presence of TSP1 (p Ͻ 0.001, n ϭ 3, two-way ANOVA). agonists diminish TSP1 secretion in a dose-dependent manner, and an antagonist of adenosine A 2A but not A 1 or A 2B receptors, completely reverses this effect. After A 2A receptor ligation, diminished intracellular mRNA content parallels diminished TSP1 production. Likewise, these same adenosine A 2A receptor agonists increase vascular tube formation by cultured human microvascular endothelial cells, and a selective A 2A receptor antagonist blocks enhanced vascular tube formation. Moreover, when the effect of endogenously released TSP1 on vascular tube formation is blocked by specific antibodies for TSP1 and its receptor CD36, there is no adenosine A 2A receptor-mediated enhancement of angiogenesis in this model. TSP1, a 420-kDa glycoprotein, is a naturally occurring inhibitor of angiogenesis that is synthesized and secreted by various cell types, including fibroblasts and endothelial cells, in response to thrombin stimulation. It is a homotrimer in which each subunit possesses multiple structural domains that specify distinct biological functions through interaction with specific receptors on the effector cells. TSP1 is widely distributed in the extracellular matrix of numerous tissues and is degraded by both extracellular and intracellular routes. TSP1 influences cell adhesion, motility, growth, and angiogenesis (Armstrong and Bornstein, 2003; Adams and Lawler, 2004; Ann Elzie and Murphy-Ullrich, 2004; IruelaArispe et al., 2004) . The antiangiogenic activity of TSP1 involves interaction with the microvascular endothelial cell receptor CD36, a transmembrane glycoprotein binding site for TSP1 on endothelial cells (Armstrong and Bornstein, 2003; Simantov and Silverstein, 2003) . The effects of TSP1 on angiogenesis are complex; TSP1 in the matrix also activates latent transforming growth factor-␤ (Guo et al., 1997) which stimulates granulation tissue (including blood vessel) formation in wounds. It is not clear whether the angiogenic or antiangiogenic effect dominates at any given site, although in the simple in vitro angiogenesis model studied, the effect of reducing TSP1 was to promote vascular tube formation.
Previous studies indicate that adenosine A 2B receptors may mediate enhanced angiogenesis (Grant et al., 2001; Feoktistov et al., 2002 Feoktistov et al., , 2003 Afzal et al., 2003) , although studies in cultured human endothelial cells and models of wound healing in A 2A receptor knockout mice are consistent with an A 2A receptor-mediated phenomenon Nguyen et al., 2003) . Human microvascular endothelial cells express mRNA for both adenosine receptor subtypes (Nguyen et al., 2003) , and it is possible that both contribute to the angiogenic effects of exposure to CGS-21680 but not MRE0094. The evidence for a role of A 2B receptors in promoting angiogenesis is derived from studies performed with a human endothelial cell line (HMEC-1) or canine retinal endothelial cells, whereas our studies were performed with human microvascular endothelial cells and in vivo studies in mouse skin. The diverse origins of the cell types involved may explain the different effects of the two different adenosine A 2 receptors on angiogenesis reported to date.
As described above, both adenosine A 2A and A 2B receptors modulate endothelial cell function, although the intracellular signaling mechanisms are unclear. Both A 2A and A 2B receptors are linked to G ␣S signaling proteins in most cell types, and this G protein is linked to activation of adenylate cyclase. In contrast, human microvascular endothelial cells do not express G ␣S protein or message (Nguyen et al., 2003) but express G olf , which may also signal via adenylate cyclase. Moreover, without pretreatment with tumor necrosis factor or interleukin-1, no cAMP response is detectable in adenosine A 2A receptor-stimulated cells (Nguyen et al., 2003) . In a parallel fashion, the adenosine A 2A receptor-stimulated increase in VEGF message is significantly greater in human microvascular endothelial cells pretreated with tumor necrosis factor. Grant et al. (2001) have reported that adenosine A 2B receptor occupancy promotes angiogenesis via stimulation of mitogen-activated protein kinase activity. The capacity of adenosine A 2A receptors to stimulate mitogen-activated protein kinase activity in human microvascular endothelial cells has not been tested, and it is possible that the A 2A receptor signals by a mechanism shared with A 2B receptors.
The effects of both MRE0094 and CGS21680 on TSP1 secretion seem to be biphasic. Because HMVECs express neither A1 nor A3 receptors and the pharmacological data are consistent with an A 2A receptor-mediated effect, it is difficult to associate the effects of these agents with another adenosine receptor. It is possible that the A 2A receptor agonist sensitizes the A 2A receptor to further stimulate even the prolonged inhibitions studied here. This phenomenon has not been reported previously.
Our studies identify A 2A receptor activation as a key switch for turning on angiogenesis, similar to hepatocyte growth factor/scatter factor stimulation. Hepatocyte growth factor/scatter factor acts in parallel with A 2A receptor-stimulated phenomena: the ligand-receptor interaction stimulates endothelial cells to proliferate and migrate in vitro, induces blood vessel formation in vivo (Bussolino et al., 1992; Grant et al., 1993; Rosen and Goldberg, 1995) , diminishes TSP1 (Dong et al., 2001) , and induces VEGF expression in human cancer cells, microvascular endothelial cells, and monocytoid cells. TSP1 shut-off plays an important role in tumor suppression; ectopic expression of TSP1 markedly inhibits tumor formation through the suppression of angiogenesis (Zhang et al., 2003) . Because ischemic tumors release large amounts of adenosine (Gao et al., 2001) , there may be a role for adenosine in promoting tumor growth by suppressing TSP1 production and the immune response to the tumor. Thus, the observation that adenosine A 2A receptors promote angiogenesis in vitro and in vivo suggests that specific adenosine A 2A receptor antagonists may be useful in the treatment of angiogenesis-dependent tumors. 
